Aciclovir 400mg tablets

País: Reino Unido

Língua: inglês

Origem: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredientes ativos:

Aciclovir

Disponível em:

Crescent Pharma Ltd

Código ATC:

J05AB01

DCI (Denominação Comum Internacional):

Aciclovir

Dosagem:

400mg

Forma farmacêutica:

Oral tablet

Via de administração:

Oral

Classe:

No Controlled Drug Status

Tipo de prescrição:

Valid as a prescribable product

Resumo do produto:

BNF: 05030201; GTIN: 5017123003141

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Aciclovir 400 mg tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 400 mg tablet contains 400 mg of aciclovir.
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Tablet
White, round, biconvex tablets with a diameter of 11mm.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Aciclovir tablets are indicated for the treatment of herpes simplex
virus
infections of the skin and mucous membranes including initial and
recurrent
genital
herpes
(excluding
neonatal
HSV
and
severe
HSV
infections
in
immunocompromised children).
Aciclovir tablets are indicated for the suppression (prevention of
recurrences)
of recurrent herpes simplex infections in immunocompetent patients.
Aciclovir tablets are indicated for the prophylaxis of herpes simplex
infections
in immunocompromised patients.
Aciclovir tablets are indicated for the treatment of varicella
(chickenpox) and
herpes zoster (shingles) infections.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Dosage in adults
_Treatment of herpes simplex infections:_ 200 mg of aciclovir should
be taken
five times daily at approximately four hourly intervals omitting the
night time
dose. Treatment should continue for 5 days, but in severe initial
infections this
may have to be extended.
In severely immunocompromised patients (e.g. after marrow transplant)
or in
patients with impaired absorption from the gut the dose can be doubled
to 400
mg of aciclovir or alternatively intravenous dosing could be
considered.
Dosing should begin as early as possible after the start of an
infection; for
recurrent episodes this should preferably be during the prodromal
period or
when lesions first appear.
_Suppression of herpes simplex infections in immunocompetent
patients:_ 200
mg of aciclovir should be taken four times daily at approximately
six-hourly
intervals.
Many patients may be conveniently managed on a regimen of 400 mg of
aciclovir twice daily at approximately twelve-hourly intervals.
Dosage
titration